BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18027227)

  • 21. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The need for more efficient trial designs.
    Golub HL
    Stat Med; 2006 Oct; 25(19):3231-5; discussion 3313-4, 3326-47. PubMed ID: 16819752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA perspective on trials with interim efficacy evaluations.
    Temple R
    Stat Med; 2006 Oct; 25(19):3245-9; discussion 3326-47. PubMed ID: 16847824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An adaptive approach to implementing bivariate group sequential clinical trial designs.
    Todd S
    J Biopharm Stat; 2003 Nov; 13(4):605-19. PubMed ID: 14584711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive group sequential test with changing patient population.
    Feng H; Liu Q
    J Biopharm Stat; 2012; 22(4):662-78. PubMed ID: 22651107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interim analysis in clinical trials: a methodological guide].
    Muñoz Navarro SR; Bangdiwala SI
    Rev Med Chil; 2000 Aug; 128(8):935-41. PubMed ID: 11129556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sequential analysis in clinical and epidemiological research].
    van der Tweel I; Schipper M
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2348-52. PubMed ID: 12510397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
    Bénichou J; Lepage E; Chastang C
    Nouv Rev Fr Hematol (1978); 1987; 29(1):87-91. PubMed ID: 3473443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.